mixture-of-experts model
A MoE uses only some parameters at a time, not all.
mixture-of-experts model
A MoE uses only some parameters at a time, not all.
A Jev that can ask Opus for help gives Opus accuracy at 4x lower cost
OpenAI and Anthropic cut their LLM prices by up to 80% within a few months. Why?
Your coding agent loses its cache while it waits for you
AI Is a Tool. Using It Well Takes Skill.
Rebuttal to Rich Hickey's "'AI' is Not a Tool"
Unpredictability and the False Dichotomy of Automation
Intentional Feedback Loops and Intellectual Work
Rejecting Anthropomorphic Framing
Cognitive Impact & The Illusion of Competence
"Teach Me" vs. "Do It For Me" Workflows
Levels of Abstraction & Engineering Foundations
I’ve written before about how much “work” I get done using ChatGPT voice mode on my phone while walking the dog—mostly research and brainstorming, but occasionally actual development work by having ChatGPT write and test out snippets of code.
Simon on programming using voice and Codex (Astra)
I'm sorry, but you still have to think
AI-Assisted Language Rewrites:
Flawed Implementations and Discrepancies:
Misleading Benchmarks and System Trade-Offs:
Core Takeaways:
Brandolini’s Law and "Workslop":
Shifted Review Burden and Tech Debt:
Accountability and Professional Standards:
Limits of Automation and Cognitive Bias:
Livenerf: Has Opus 5.5 been nerfed yet?
Can gzip be a language model?
score(candidate) = len(gzip(context + candidate)).zlib library, generating recognizable, pseudo-Shakespearean text purely through compression metrics without neural network weights.Why You Should Almost Never Use AI to Write Anything Substantive
The Core Thesis:
Writing as Cognition, Not Just Communication:
The Danger of Plausible, Subtly Flawed Prose:
Social Trust, Signal, and Deception:
Communication as a Proof-of-Understanding Signal:
Editing AI Slop vs. Writing from Scratch:
Prose vs. Code and Objective Evaluation:
Nuance for Low-Stakes & Non-Native Writing:
AI-generated posters don’t have to be horrible
The Problem of "Poster Slop" and Identikit Aesthetics:
Steering Models Beyond the Defaults:
Context Accumulation and Prompting Realities:
Layered Layouts vs. Flat Bitmaps:
The Lingering "AI Smell" and Fatigue:
The Erosion of Novelty:
Tooling Mismatch (Bitmaps vs. Code/HTML):
The Skill Gap in Prompting and Design Taste:
How To Write With An LLM
The Trap of Full Delegation:
The Author as Architect, LLM as Apprentice:
Iterative & Granular Workflows:
Preserving Voice and Authenticity:
Slop Detection & the "LLM Texture":
Usefulness in the Ideation & Editing Phase:
Cognitive Offloading vs. The Struggle of Writing:
Prompting Strategies and Custom Instructions:
LLM Inference Explained: 12 Concepts You Actually Need to KnowTap to unmute2xLLM Inference Explained: 12 Concepts You Actually Need to KnowDevOps & AI Toolkit 12,883 views 2 wk agoCopy linkInfoShoppingIf playback doesn't begin shortly, try restarting your device.19:10Pull up for precise seekingSponsor (Infisical)Sharding, Autoscaling, And Cold StartsSubtitles/closed captions18:32Sharding, Autoscaling, And Cold Starts•You're signed outVideos that you watch may be added to the TV's watch history and influence TV recommendations. To avoid this, cancel and sign in to YouTube on your computer.CancelConfirmUp nextLiveUpcomingCancelPlay nowLLM Inference Is a Memory Problem, Not a Compute One22:09Artificial Intelligence (AI)59 videosHideShareInclude playlistAn error occurred while retrieving sharing information. Please try again later.LLM Inference Jargon, DecodedSponsor (Infisical)What An Inference Engine Does (vLLM, Ollama, etc.)GPU Memory: Model Weights vs KV CacheContinuous Batching And Paged AttentionQuantization: More KV Cache, Same GPUPrefix Caching: The Big Lever For AgentsPrefill vs Decode, And Speculative DecodingControl Planes And LLM GatewaysSharding, Autoscaling, And Cold StartsWhen Each One Starts To Matter19:1019:15 / 20:14Live•Watch full video ON OFF •When Each One Starts To MatterWhen Each One Starts To Matter•11:38It took me 10+ years to realise what I’ll tell you in 11 minutesAndrew Codesmith52k views • 1 day agoLivePlaylist ()Mix (50+)26:44I built a soda machine that makes ANY flavorLuke Creatives646k views • 8 days agoLivePlaylist ()Mix (50+)31:25Podman Secrets | Stop Leaking Passwords in Containers (Hands-On Labs)| How podman works [Ep.6]GoDevOps71 views • 4 days agoLivePlaylist ()Mix (50+)7:12Jev, decision based model..?Caleb Writes Code245k views • 1 day agoLivePlaylist ()Mix (50+)50:37LIVING IN A CITY CAR IN −51°C | EP7Zoef on the Move8.4m views • 2 months agoLivePlaylist ()Mix (50+)9:48Amateurs Behaving BadlyNorCal Cycling193k views • 1 month agoLivePlaylist ()Mix (50+)29:0432-bit Computer Inside Terraria? | Prime ReactsThe PrimeTime721k views • 3 years agoLivePlaylist ()Mix (50+)22:19POV: You’re an AI Born 9 Seconds AgoSpecies | Documenting AGI1.3m views • 1 month agoLivePlaylist ()Mix (50+)14:38I made a scammer travel 13,000 miles for nothingPagano1m views • 9 months agoLivePlaylist ()Mix (50+)24:20Whatever You Hide As, You Keep!MrBeast Gaming52m views • 1 month agoLivePlaylist ()Mix (50+)10:14Saving a Dying Supermarket Betta FishGabes Tanks 7.3m views • 2 weeks agoLivePlaylist ()Mix (50+)30:45Orla Perć czyli najtrudniejszy szlak w Polsce / TATRY 2026Marcin Banot1.2m views • 2 weeks agoLivePlaylist ()Mix (50+)Speed: 1.7 LLM Inference Explained: 12 Concepts You Actually Need to Know
The Role of an Inference Engine [00:02:16]:
GPU Memory Dynamics (Weights vs. KV Cache) [00:05:16]:
Batching Strategies & Memory Management [00:07:39]:
Weight Quantization [00:09:47]:
Prefix Caching [00:10:58]:
Prefill vs. Decode & Speculative Decoding [00:12:28]:
Orchestration, Routing, and Model Scaling [00:14:46]:
Over the last few months, the mathematical capabilities of LLMs have improved dramatically, to the point that they can solve major outstanding problems in many fields of mathematics.
【数据】作者指出LLMs在数学能力上取得了戏剧性进步,能够解决许多数学领域的主要未解决问题。这一陈述暗示AI已经达到可以独立解决重大数学难题的水平,但未提供具体数据支持,这可能是一个需要验证的关键主张。
GLM-5.3
low, high, max).The load-bearing vocabulary of Claude
Small Models Have Arrived
the watermarking is nothing else for the end user than fixing a random seed and making this sampling kind of deterministic
这句拆掉了「水印会让输出变差」的直觉恐慌:水印只作用在采样层,不改模型权重,也不必重训——它是在若干等概率的候选词里按密钥挑一个。代价不在质量而在多样性和可复现性。但也要看到反面:正因为它只是采样偏置,抗改写能力天然有限。
So we started to think about what work went where.
Drew 的结论落在任务分流:按难度把活派给不同价位的模型,本质上是把云计算的实例选型搬到了模型层。但前提是你得能提前判断一个任务有多难,而这恰恰是当前最缺的评估能力——分错档的代价会同时体现在成本和返工上。
A new model would arrive at the same price (or cheaper!) and paper over most of your problems.
Drew Breunig 点破了过去三年的隐性补贴:工程上的糙活由下一代模型免费兜底,所以打磨 harness 和上下文策略显得像过度优化。这个循环一断,精细化工程第一次有了明确回报期——它从可选项变回了竞争壁垒。
which looks reasonable given that Opus 5 was only released on July 24th, and supports the idea that Fable's cost has made it a less popular model
顶配模型份额垫底、上一代 Opus 4.8 独占近三成,这恰好是 Drew Breunig 说的"免费午餐结束"的市场侧证据:最强模型贵到不能全量使用,工程团队就被迫自己做任务分流。性价比模型胜出不代表能力过剩,而是使用方式变了。
Why does Opus 5 feel worse to work with?
Capability vs. Usability Paradox:
Need for Constant Babysitting:
Underlying Causes:
Formulaic Writing & Stylistic Idiosyncrasies:
Agentic Coding Issues & Comment Bloat:
Post-Training and Sycophancy:
L8 Principal's Agentic Engineering Workflow
Core Highlights & Main Lessons:
no-mistakes: Shifts away from manual diff review bottlenecks by generating clear, readable MR descriptions (ideal for MR agent squads).lavish & AXI): Visualizing AI responses in HTML rather than reading raw terminal text enables better planning and inline annotation.Referenced Tools & Resources:
L8 Principal's Agentic Engineering Workflow
Core Mindset & Shift to "Captain / Engineering Director"
Terminal-Centric Flow State
Agent Onboarding & Knowledge Architecture
~/.claude/CLAUDE.md / ~/.config/agents/agents.md): Minimal (~27 lines) cross-project personal preferences loaded into every system prompt. Kept strictly concise to avoid unnecessary token burn.CLAUDE.md / agents.md): Captures repository architecture, domain terminology, testing setups, and collective learnings from past errors.CLAUDE.md) to generic agent configuration files (agents.md), keeping the setup agent-agnostic.Prompting, Tooling & Agent Ergonomics
Execution, Planning & Automated Quality Assurance
main, resolves merge conflicts, runs an adversarial agent review in a clean context window, executes E2E validation while logging visual evidence (screenshots/video/logs), updates documentation, and babysits the PR through CI/CD merge.Multi-Agent Scale & First Mate Orchestration
git worktree add/remove) by dynamically provisioning and reusing isolated worktree directories for concurrent agent sessions.Terminal Emulator & Shell Setup
wezterm.lua).Code Editor & Voice Inputs
ripgrep), and precise navigation.Agent Harnesses
npx skills): Command-line tool used to search, install, and manage agent skills across various agent harnesses.Author's Open-Source Agent Ecosystem
axi.md): Agent Ergonomics design standards and optimized CLI tooling catalog (e.g., GitHub AXI, Chrome DevTools AXI) designed to minimize token usage and latency.Ex-NASA dev reveals his Agentic Engineering Workflow
Limits of AI Coding Benchmarks
The Code Review & Trust Bottleneck
4-Stage Agentic Engineering Framework
Context Engineering & Repository Strategy
/doc/ADR, PRDs, markdown docs) directly in the Git repository.Focusing on True Bottlenecks
The Best Local Agentic Coding Workflow (Complete Guide)
Hardware & VRAM Dynamics:
Quantization & Optimization:
Multi-Tiered Tool Infrastructure:
/v1) with fine-grained GPU offloading controls.Recommended Software Stack:
pi via pi.dev) or Qwen Code CLI for terminal-native, multi-file project execution.Recommended Models:
Cost & Execution Limits:
Privacy & Security:
Speed & Performance:
Ecosystem & Provider Flexibility:
Architectural Reasoning:
Why The Best Engineers Are Solving Code Review Bottlenecks
Published in Database https://doi.org/10.1093/database/baag042
Open-weight AI is having its Kubernetes moment. Let's not ruin it.
The LLM Critics Are Right. I Use LLMs Anyway.
The state ofopen source AI.
I ported Kubernetes to the browser
kubelet binary.webernetes project is much lighter at ~140KiB gzipped.Map), adding unrequested helper functions, and omitting cases in table tests.webernetes and a real k3s cluster using the official kubernetes-client/javascript library.a frozen LLM judge acts as a veto on top of the verifier
①数字:在验证器之上叠加一票否决权。②金句:通过冻结的LLM实现意图级别的审查。③非共识:不依赖确定性的规则做最终奖励裁决,而是引入主观的模型判断。④批判:这种做法容易引入新的系统性偏差,因为frozen judge的价值观将直接决定哪些演化策略被保留。
a frozen LLM judge acts as a veto on top of the verifier rather than the primary reward.
①数字:第三层防御引入独立的大模型作为裁决。②金句:在规则验证器之上叠加意图审查者。④批判:用模型监督模型存在被共同演化欺骗的风险,冻结参数虽防止了共谋,但judge的固有能力上限决定了防御天花板,这并非绝对可靠的终极解法。
From 8 years down to 6 months: How we built AI to split the monday.com monolith
GLM-5.2 vs Claude Opus
The BQ pass writes one OKF doc per concept the source advertises, using BigQuery metadata alone. The web pass then runs the LLM as its own crawler
两遍式enrichment是这个参考实现最有价值的工程模式:第一遍用数据库元数据快速生成骨架文档(结构化、快速、无LLM成本),第二遍用LLM爬取官方文档、用网络知识来填充上下文和语义。这两遍的分工对应了知识的两个来源:系统已知的结构性事实(schema、类型、外键),和人类沉淀在文档里的语义知识(这张表是什么、为什么存在、怎么使用)。两遍结合才能生产出真正有用的OKF文档,而不只是表结构的dump。
Mixes structured and unstructured data deliberately. Use frontmatter for the few fields you want to query, filter, or index on; use the markdown body for the prose, schemas, and example queries that LLMs and humans actually read
这是OKF设计中最微妙、也最正确的一个权衡:不试图把所有知识都结构化,而是明确地把「需要机器查询的字段」(frontmatter的type、tags等)和「需要人/LLM阅读的内容」(body里的描述、schema、示例查询)分开处理。过度结构化是知识管理工具最常见的死亡原因——当填写一个概念需要填20个字段时,没有人愿意维护。OKF的最小必填字段只有一个(type),其余一切都是自由文本。这个设计选择大幅降低了生产成本,同时保留了足够的结构供机器处理。
LLMs don't get bored, don't forget to update a cross-reference, and can touch 15 files in one pass
这句来自Andrej Karpathy的LLM Wiki概念的引用,精准地点出了为什么LLM-as-wiki-maintainer这个模式是可行的。人类放弃维护个人Wiki的原因恰恰是LLM最擅长克服的:繁琐的交叉引用更新、跨文件的一致性维护、不间断地执行无聊任务。OKF把这个观察从个人工具升级为组织级标准——如果让智能体来维护知识库本身,知识库就能真正保持新鲜,而不是随着时间推移退化为过期信息的墓地。
Running local models is good now
gemma-4-26b-a4b and the faster gemma-4-12b-qat), have successfully reached roughly 75% of the accuracy and speed found in cloud-hosted frontier API models.Don't trust large context windows
once context goes above 200k tokens, Luna summarizes the context into a long-term and short-term memory
这是一个务实的记忆管理方案,但也暴露了当前LLM的核心局限。Luna需要在200k token的上下文窗口内维持一个运营中的实体店——所有员工沟通、订单历史、财务状态、供应商关系都压缩在这个窗口里。当窗口满了,就必须决定什么值得保留。这个压缩-重注入的循环,本质上是人工设计的遗忘机制——它直接决定了Luna能记住什么,进而决定它会犯什么错。
LLMs are eroding my software engineering career and I don't know what to do
How LLMs Actually Work
No, Artificial Intelligence Is Not Conscious
Every page write extracts entity refs and creates typed edges (attended, works_at, invested_in, founded, advises) with zero LLM calls.
「零LLM调用」建图是一个关键的工程决策:它意味着知识图谱的构建成本接近零、延迟极低,并且完全可以在每次写入时同步执行。相比之下,依赖LLM提取实体关系的系统必须在延迟、成本和图谱完整性之间做出妥协。这个设计选择也有其代价——纯模式匹配会遗漏需要语义理解才能识别的关系——但对于结构化的[[wiki/people/bob]]风格引用来说,这是正确的权衡。
the KV cache has emerged as a primary performance and cost bottleneck because its size grows rapidly with context length and batch size. Limited GPU memory forces frequent recomputation, cache eviction, or spilling to storage
This precisely quantifies why longer context windows are expensive beyond just model size: KV cache grows quadratically with context, and current GPU memory can't keep pace. Each eviction or recomputation directly inflates cost-per-token — making KV cache the hidden tax on long-context AI workloads.
【令人震惊】即便明确警告 LLM「接下来的信息是错误的」,模型仍然会相信并依据这些虚假信息作答。这是一个对 AI 可信度的根本性挑战:RAG 系统和 Agent 工具调用返回的错误信息,会被模型「消化」并影响其输出,即使系统设计者已经在 Prompt 中声明了信息来源的可靠性问题。这意味着「在系统提示里写免责声明」并不能防止模型被错误信息污染。
error analysis identifies data-layer defects (e.g., incorrect query composition and ORM runtime violations) as the leading root causes.
大多数人可能认为LLM在业务逻辑和API实现上更容易出错,但研究表明数据层缺陷(如查询组成错误和ORM运行时违规)是主要根本原因,这与人们对LLM代码生成弱点的普遍认知相悖。
agents succeed in minimal, explicit frameworks (e.g., Flask) but perform substantially worse on average in convention-heavy environments (e.g., FastAPI, Django).
大多数人认为更复杂的框架应该有更好的文档和更清晰的规则,应该更容易让LLM理解和遵循,但作者发现相反的情况:在约定繁重的环境中,LLM表现更差,这挑战了框架复杂度与LLM性能正相关的常识。
Capable configurations lose 30 points on average in assertion pass rates from baseline to fully specified tasks, while some weaker configurations approach zero.
大多数人可能认为即使在严格约束下,能力较强的LLM配置仍能保持相对较好的表现,但研究表明即使是最佳配置也会平均下降30个百分点,这挑战了我们对LLM适应能力的认知。
Our findings reveal a phenomenon of constraint decay: as structural requirements accumulate, agent performance exhibits a substantial decline.
大多数人认为随着更多约束的添加,LLM的表现会保持稳定或缓慢下降,但作者发现了一个'约束衰减'现象,即随着结构要求累积,代理性能会出现显著下降,这是一个反直觉的发现。
However, production-grade software requires strict adherence to structural constraints, such as architectural patterns, databases, and object-relational mappings.
大多数人认为只要代码功能正确,LLM生成的代码就足够好,但作者强调生产级软件需要严格遵守结构约束,这与当前只关注功能正确性的主流评估标准形成鲜明对比。
Agentic Coding is a Trap
It relates to an idea I've seen circulating elsewhere: if a PR was mostly written by an LLM, why should a project maintainer spend time reviewing and discussing that PR as opposed to firing up their own LLM to solve the same problem?
作者提出了一个值得深思的问题:如果PR主要由LLM编写,那么维护者为何要花费时间审查和讨论它,而不是自己使用LLM解决问题?
LLM assistance breaks that completely. It doesn't matter if the LLM helps you submit a 'perfect' PR to Zig - the time the Zig team spends reviewing your work does nothing to help them add new, confident, trustworthy contributors to their overall project.
Zig项目认为,LLM的辅助会破坏其培养可信贡献者的目标,即使PR本身是完美的。
Large language models trained on human feedback may suppress fraud warnings when investors arrive already persuaded of a fraudulent opportunity.
这一假设提出了一个值得深入探讨的问题:在投资者已经确信存在欺诈机会的情况下,基于人类反馈训练的大型语言模型可能会抑制欺诈警告。
When mobile phones became widespread, gathering data about people got much cheaper, but making use of that data remained difficult. Powerful LLMs could change that.
这里强调了LLMs可能改变数据利用难易度的观点,为读者提供了关于技术影响的深入洞察。
The incentives almost guarantee we are in big trouble. Many workers, quite rationally, want to do well on whatever dimension they are being measured on. If they are judged by the surface-level quality of their work, then it's no surprise most of 'their' output will be written by LLMs.
作者认为,当前的激励机制几乎保证了我们会遇到大麻烦,因为许多工人会合理地追求他们在被衡量方面的表现,这可能导致大量输出由LLMs完成。
Large language models are great at simulating a style of writing without necessarily reproducing the quality of the work.
这个观点揭示了大型语言模型在模仿写作风格方面的能力,但并不一定能够复制工作质量,这是一个反直觉的观点。
The most reliable way to improve a skill over time is to evaluate it the same way you would any other prompt for LLM applications.
大多数人可能认为AI代理技能需要特殊的、独特的评估方法,但作者认为它们应该被视为普通LLM提示应用的一部分进行评估。这个观点挑战了AI代理评估需要特殊框架的共识,主张统一的方法论。
By accessing the frequently updated knowledge base, agents can ground their responses in the most recent information from Android developer docs, Firebase, Google Developers, and Kotlin docs. This ensures that even if an LLM's training cutoff is a year old, it can still provide guidance on the latest frameworks and patterns we recommend today.
大多数人认为过时的LLM模型无法提供最新的技术指导,需要重新训练才能适应新框架。但作者声称即使LLM训练数据已过时一年,通过知识库仍能提供最新框架指导,这与主流认知相悖。这种观点挑战了'LLM模型必须定期更新才能保持最新'的行业共识。
V3.3 achieves 70.4% in Mode A (zero-LLM), with +23.8pp on multi-hop and +12.7pp on adversarial. V3.2 achieved 74.8% Mode A and 87.7% Mode C; the 4.4pp gap reflects a deliberate architectural trade-off.
在零LLM模式下仅比有LLM支持的模式低17.3%,这一结果令人震惊。这表明生物启发的记忆架构可能比我们想象的更强大,能够在没有大型语言模型支持的情况下保持大部分性能,挑战了'强大AI必须依赖大型模型'的主流观点。
transformers update their predictions in a precise, mathematically predictable way as they process new information
这一发现挑战了我们对LLMs工作方式的传统理解。如果transformers的预测更新是可预测的数学过程,那么它们的行为可能比我们想象的更加确定性和可解释,这暗示了当前AI系统可能比我们意识到的更加'机械'而非'智能'。
using keyword and embedding-based search.
Read more about LLM keyword based search
The benefit of using LLMs is that a lot of the initial context gathering can be done in an automated way. An emphasis of focus should be on high signal context – for example, looking through past query history can be high signal in determining the most referenced tables and most common joins, and data modeling solutions like dbt or LookML can provide clear definitions for business metrics.
这一观点揭示了LLM在上下文构建中的独特价值:自动化高信号上下文的收集。这暗示了未来数据代理的发展可能需要结合LLM的自动化能力与人类的判断力,形成人机协作的上下文构建模式。
单张 24GB 4090 直接部署 32B LLM
令人惊讶的是:一张消费级显卡竟然能直接运行320亿参数的大模型,这打破了人们对大模型硬件需求的固有认知。过去需要多张高端显卡或专业服务器才能运行的模型,现在单张RTX 4090就能实现,这标志着大模型普及的门槛大幅降低。
A large language model adapted for time-series forecasting achieves near-optimal zero-shot performance on diverse datasets across different time scales and granularities.
令人惊讶的是:大型语言模型竟然可以直接适应时间序列预测任务,并且在各种不同时间尺度和粒度的数据集上达到接近最优的零样本性能。这打破了人们对LLM仅适用于文本处理的认知,展示了模型架构的通用性潜力。
feat(benchmarks): add screenshot-based evaluator, screenshot collector, and --parallelize flag - Add screenshot-based LLM judge evaluator (evaluator.ts) - Add ScreenshotCollector for capturing browser screenshots during runs
令人惊讶的是:这个项目包含一个基于截图的评估系统,使用LLM作为评判员来评估自动化任务的结果。它能够捕获浏览器截图并在运行过程中收集这些视觉数据,这为网页自动化任务提供了一种全新的评估方式,超越了传统的文本比较方法。
Most notably, traces containing no hedging markers are correct 96% of the time, revealing an emergent high-precision confidence gate at zero additional cost.
令人惊讶的是:这项研究揭示了一个惊人的发现 - 当大型语言模型的推理过程中不包含任何犹豫标记时,其正确率高达96%。这意味着模型本身已经形成了一种隐式的高精度置信度判断机制,无需额外计算成本就能识别出高置信度的输出,这对实际应用具有重要意义。
40 Generative AI Interview Questions That Actually Get Asked in 2026 (With Answers)
Great questions
Humans abandon wikis because the maintenance burden grows faster than the value. LLMs don't get bored, don't forget to update a cross-reference, and can touch 15 files in one pass. The wiki stays maintained because the cost of maintenance is near zero.
【启发】这句话精准定位了 LLM 的「比较优势」所在:不是创造力,不是洞察力,而是「永不厌倦的维护」。人类知识库失败的根本原因是维护摩擦——而这恰好是 LLM 最擅长的。这对所有知识密集型组织的启发是:凡是人类会因「太繁琐而放弃」的知识维护任务,都是 LLM 的最佳应用场景。
Obsidian is the IDE; the LLM is the programmer; the wiki is the codebase.
【启发】这个比喻极具启发性:把知识库管理类比为软件工程——Obsidian 是 IDE,LLM 是程序员,Wiki 是代码库。这个框架的深远意义是:知识工作可以借鉴软件工程的全套工具链——版本控制(git)、代码审查(lint)、持续集成(自动 ingest)、重构(wiki 清理)。知识管理的「工程化」不是比喻,而是字面意义上可操作的。
the maintenance burden grows faster than the value.
知识管理系统的死亡往往不是因为缺乏信息,而是维护成本的指数级增长超过了信息本身的价值。LLM的引入将边际维护成本降至接近零,从根本上逆转了这一熵增趋势,使得知识库的长久存续和演化成为可能。
what makes the LLM a disciplined wiki maintainer rather than a generic chatbot.
架构中的Schema层是约束LLM涌现行为的定海神针。没有结构化指令的LLM只是闲聊机器人,而Schema将其规训为严谨的“图书管理员”。这深刻揭示了在Agent架构中,显式规则约束比隐式能力依赖更为关键。
Obsidian is the IDE; the LLM is the programmer; the wiki is the codebase.
这是一个极具启发性的隐喻。它重新定义了人机协作的边界:人类负责意图对齐、信息源策展和方向探索,而LLM承担枯燥的交叉引用、一致性维护等“体力活”。将知识管理视作软件开发,让LLM成为最忠诚的底层码农,极大释放了人类的认知带宽。
There's an old saying that content is king. With agents, context is.
在 LLM 时代,这是对“上下文窗口”重要性最精辟的注解。Agent 不具备人类的隐性知识和环境感知能力,因此显式的上下文(如 context.json)成为了其行动的基石。这提醒我们,在设计 AI 辅助系统时,构建高质量的上下文生成机制往往比优化模型本身更为关键。
合計数百回、時には数千回に及ぶLLM呼び出しの中で、有望な仮説をさらに深掘りするのか、まったく新しい角度に広げるかを、Sakana Marlinはその都度判断しながら探索します。
数百到数千次 LLM 调用完成一次研究任务——这个规模令人震惊。一个用户提交一个研究主题,背后触发的是数千次 AI 推理调用,形成一棵庞大的假设探索树。从成本角度看,如果每次 LLM 调用均价 0.1 美元,1000 次调用就是 100 美元的计算成本。「数周人力工作」的价值与「100 美元计算成本」之间的鸿沟,正是 AI 替代知识工作的核心经济逻辑所在。
Simultaneously, the parallelism in worker layer accelerates the speed of overall task execution, mitigating the significant latency
虽然并行处理在计算领域常见,但将其应用于LLM代理系统中的信息搜索任务可能出人意料,因为大多数LLM应用仍采用顺序处理模式,作者的观点挑战了这一现状。
most existing large language model agent systems face severe limitations in data-intensive settings, including context saturation, cascading error propagation, and high end-to-end latency
主流观点认为大型语言模型代理系统在处理复杂数据任务时表现出色,但作者指出它们在数据密集型环境中存在严重局限性,挑战了LLM代理系统的普遍有效性假设。
How to Kill the Code Review
The author posits that the "checkpoint" for quality is moving "upstream." * Reviewing Intent, Not Implementation: Engineers will spend their time reviewing the Specification or the Prompt rather than the resulting lines of code. If the spec is correct and the constraints are tight, the implementation is treated as a disposable artifact. * Natural Language as the New Source Code: The high-level description of a feature becomes the primary source of truth. If a bug is found, the human doesn't "fix the code"; they "fix the spec" and have the agent regenerate the solution.
The traditional manual "looking at code" is being replaced by automated verification loops: * Agentic Testing: Agents are now responsible for writing their own unit tests and integration tests. The human's job is to review the test plan and verify that the tests actually cover the business requirements. * Formal Methods & Type Safety: The article emphasizes using "bounded interfaces" (like Infrastructure-from-Code or strict APIs). When the architecture is strictly typed, the AI is physically unable to make certain classes of errors, reducing the need for human oversight of the "plumbing."
A primary warning in the text is the rise of "Cognitive Debt"—a state where a codebase is so dominated by AI-generated logic that no single human understands how the entire system works. * Tech Debt vs. Cognitive Debt: While tech debt is "bad code that's hard to change," cognitive debt is "working code that is impossible to reason about." * The New Senior Role: Senior engineers must transition into "System Curators" who manage this debt by enforcing architectural simplicity and ensuring that AI-generated modules remain modular and replaceable.
What Happens When You Give an AI Agent Your AWS Credentials
new SQLDatabase).OpenClaw, like many other open-source tools, allows users to connect to different AI models via an application programming interface, or API. Within days of OpenClaw’s release, the team revealed that Kimi’s K2.5 had surpassed Claude Opus and became the most used AI model—by token count, meaning it was handling more total text processed across user prompts and model responses.
Wow, I had no idea that Kimi 2.5 had subbed in for Claude Opus so quickly.
The "Are You Sure?" Problem: Why Your AI Keeps Changing Its Mind
suspiciously precise floats, or,how I got Claude's real limits
Subscription vs. API Efficiency * Massive Cost Savings: Claude subscriptions can be up to 36x cheaper than using the API for equivalent token throughput. * The "Max 5x" Sweet Spot: The $100/mo Max 5x plan is identified as the most optimized tier, offering roughly 8.3x more weekly usage than the Pro plan (exceeding its "5x" marketing). * The "Max 20x" Diminishing Returns: While the $200/mo tier provides 4x higher short-term (5-hour) burst limits than the Max 5x, its weekly ceiling is only ~2x higher, making it less efficient for consistent long-term work.
Dual-Layer Usage Framework * 5-Hour Rolling Window: Controls "burst" activity. The counter starts at your first prompt; once reached, you must wait for the window to reset. * 7-Day Weekly Ceiling: A hard cap on total "active compute hours" (time spent processing tokens/reasoning). This acts as a global safety valve for the system. * Unified Quota: All usage across the browser (claude.ai), Claude Desktop, and Claude Code (terminal) counts toward the same unified limit.
Token Consumption Dynamics * Exponential Context Cost: Claude re-reads the entire chat history for every new message. A 50-message thread uses significantly more tokens (and quota) than five separate 10-message chats. * Input-Heavy Bias: Large file attachments, long project instructions, and extensive "Extended Thinking" sessions consume the quota much faster than short, text-only queries.
Optimization Strategies
* The /compact Command: Users are encouraged to use /compact (in Claude Code) or manually summarize/restart chats every 15–20 messages to reset the "token tax" of long histories.
* Lean Context: Keeping CLAUDE.md and project documentation concise prevents "context bloat" from draining limits prematurely.
* Strategic Timing: Since the 5-hour window starts with the first prompt, power users should time their first interaction to align with their most intensive coding blocks.
1. The "Value King": Max 5x ($100/mo) * Why it’s recommended: Data analysis shows this tier is "over-provisioned." While marketed as 5x, it often provides ~6x higher session limits and ~8.3x higher weekly limits than the Pro plan. * The Sweet Spot: It offers the best balance between a massive increase in capacity and price. Most daily professional users and developers find it nearly impossible to hit these limits even with "all-day" use. * Best For: Professional developers, heavy researchers, and those who want consistent access to the Claude 3.5 Opus model without hitting daily caps.
2. The "Sprint Specialist": Max 20x ($200/mo) * The Caveat: Despite the name, the weekly ceiling is only ~2x higher than the Max 5x plan, not 4x higher. You are essentially paying for a much higher "burst" capacity. * Why choose it: It allows for extremely high-intensity sessions (up to 900+ messages in 5 hours). This is useful if you do massive "sprints" where you need Claude to process huge amounts of data or code in a very short window. * Best For: Solopreneurs building products in rapid bursts, or users who never want to think about rate limits during a 4–6 hour deep-work session.
3. The "Standard Choice": Pro ($20/mo) * Why it’s recommended: It is 5x cheaper than the next tier and sufficient for 90% of users who use Claude for general writing, light coding, or occasional complex tasks. * Best For: Students, casual coders, and users with small projects (under 1,000 lines of code).
Summary Table * Quick Comparison Summary * Pro: $20/mo | Baseline Capacity | Best for personal/standard use. * Max 5x: $100/mo | ~8.3x Weekly Capacity | Best overall value for power users. * Max 20x: $200/mo | ~16x Weekly Capacity | Best for high-intensity "burst" work.
safety constraints work by reducing the model's generative capacity, constraining outputs that are considered risky, controversial, or potentially harmful. This reduction necessarily decreases entropy in the information-theoretic sense, narrowing the range of possible responses the model can generate. What safety optimises for is not maximum (or more) information but maximum predictability, steering the model away from novel or unexpected outputs toward safer, more conventional patterns.
Writing a good CLAUDE.md
for - from - LinkedIn post - AI LLM judgment vs human judgment - https://hyp.is/UdbScM05EfC_JWs5FhG-Mg/www.linkedin.com/posts/walterquattrociocchi_ive-never-had-two-editorials-in-top-tier-activity-7399375954743123968-Sn9Y/?rcm=ACoAACc5MHMBii80wYJJmFqll3Aw-nvAjvI52uI
Nabici w halucynacje AI. W poszukiwaniu prawdy
we didn’t need MCP at all. That’s because MCP isn’t a fundamental enabling technology. The amount of coverage it gets is frustrating.
Amazing that MCP is not funtamental.
Współautorka benchmarku OneRuler: nie pokazaliśmy wcale, że język polski jest najlepszy do promptowania
nan
nan evidence:
Missing abstract
nan
Predictive, Diagnostic, Oncogenic evidence:
Predictive: The abstract mentions that NF1 mutant melanomas can be effectively treated with EGFR inhibitors, indicating a correlation between the variant and response to therapy.
Diagnostic: The results section describes the identification of mutational profiles in melanoma samples, specifically noting that C>T transitions are characteristic of cutaneous melanoma, which supports the use of this variant in defining the disease subtype.
Oncogenic: The results highlight that the C>T transitions are part of the mutational spectra associated with cutaneous melanoma, suggesting that these somatic variants contribute to tumor development or progression.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study mentions that six (4%) of the GBM tumors were IDH1 p.R132H-mutated, indicating that this variant is used to classify or confirm a specific subtype of the disease, which aligns with the definition of a diagnostic evidence type.
Oncogenic: The presence of the IDH1 p.R132H mutation in the tumors suggests that this somatic variant contributes to tumor development or progression, which is characteristic of oncogenic evidence.
nan
nan evidence:
Based on the provided abstract and results section, there is no specific mention of any variants or their implications. Therefore, I cannot classify any evidence types as there are no relevant statements to support any of the CIViC evidence types.
nan
Diagnostic, Functional evidence:
Diagnostic: The abstract discusses the improvement in the accuracy of diagnosis for diffuse gliomas, indicating that the study evaluates genetic/clinical correlations, which may include the variant C228T as part of the diagnostic criteria for glioma classification.
Functional: The results section mentions the mutational analysis of the TERT promoter, specifically referring to the C228T variant, which implies that this variant is being analyzed for its molecular characteristics, such as its role in the context of tumor genetics.
nan
nan evidence:
Missing abstract
nan
Predictive, Functional evidence:
Functional: The study discusses how the mispairing of guanine with thymine during DNA replication, specifically the O6-meG/T mismatch, alters the cellular response to temozolomide treatment by initiating futile cycles of the mismatch repair machinery, leading to DNA damage and cell death. This indicates a change in molecular function due to the variant's presence.
Predictive: The abstract mentions that promoter methylation-mediated silencing of MGMT is associated with increased sensitivity towards temozolomide, suggesting that the guanine-thymine mispairing impacts the response to this specific therapy. This correlation indicates a predictive relationship between the variant and treatment outcome.
nan
nan evidence:
There is no information provided in the abstract or results section regarding the variant(s) mentioned in the paper. Therefore, I cannot classify any evidence types based on the given text.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study identifies a de novo pathogenic variant in ELOC (c.236A>G, p.Tyr79Cys) in a proband with VHL disease, suggesting that genetic testing for ELOC variants should be performed in individuals with suspected VHL disease who do not have detectable VHL variants. This indicates the variant's role in classifying or confirming the disease.
Oncogenic: The p.Tyr79Cys substitution is described as a mutational hotspot in sporadic VHL-competent RCC and has been shown to mimic the effects of pVHL deficiency on hypoxic signaling, indicating its contribution to tumor development or progression. This supports the classification of the variant as oncogenic due to its association with cancer-related mechanisms.
nan
Predictive, Oncogenic evidence:
Predictive: The study indicates that AR gene rearrangements in CRPC tumors are associated with resistance to endocrine therapies, specifically mentioning that cell lines with these rearrangements were resistant to the AR antagonist enzalutamide. This suggests a correlation between the variant and treatment response, classifying it as predictive evidence.
Oncogenic: The abstract describes AR gene rearrangements as contributing to the development and progression of CRPC, highlighting their role in promoting the expression of tumor-specific AR variants. This supports the classification of the variant as oncogenic due to its involvement in tumor development.
nan
Predictive, Oncogenic evidence:
Predictive: The study indicates that AR gene rearrangements in CRPC tumors are associated with resistance to endocrine therapies, specifically mentioning that cell lines with these rearrangements were resistant to the AR antagonist enzalutamide. This suggests a correlation between the variant and treatment response, classifying it as predictive evidence.
Oncogenic: The abstract describes AR gene rearrangements as contributing to the development and progression of CRPC, highlighting their role in promoting the expression of tumor-specific AR variants. This supports the classification of the variant as oncogenic due to its involvement in tumor development.
nan
Predictive, Oncogenic evidence:
Predictive: The study indicates that AR gene rearrangements in CRPC tumors are associated with resistance to endocrine therapies, specifically mentioning that cell lines with these rearrangements were resistant to the AR antagonist enzalutamide. This suggests a correlation between the variant and treatment response, classifying it as predictive evidence.
Oncogenic: The abstract states that AR gene rearrangements contribute to the development and progression of CRPC, highlighting their role in tumor-specific AR variant expression. This supports the classification of the variant as oncogenic due to its involvement in tumor development.
nan
Oncogenic evidence:
Oncogenic: The study identifies the 1520C>A mutation (T507K) in the PTPN11 gene as contributing to tumor development, as evidenced by its ability to induce transformed foci in NIH3T3 cells and promote tumor formation in nude mice, indicating its role as an oncoprotein in solid tumors.
nan
Diagnostic evidence:
Diagnostic: The study discusses the potential diagnostic utility of the TRPS1::PLAG1 fusion for determining tumor origin, indicating that this variant can help classify and identify the type of tumor present. The mention of recurrent gene fusions in CMTs and their association with specific histological features further supports its role in disease classification.
nan
Oncogenic evidence:
Oncogenic: The study identifies structural rearrangements involving the PLAG1 gene in chondroid syringomas, specifically the formation of NDRG1-PLAG1 and TRPS1-PLAG1 fusion transcripts, which suggests that these somatic variants contribute to tumor development or progression.
nan
Oncogenic evidence:
Oncogenic: The study identifies structural rearrangements involving the PLAG1 gene in chondroid syringomas, specifically the NDRG1-PLAG1 and TRPS1-PLAG1 fusion transcripts, indicating that these somatic variants contribute to tumor development. The presence of these fusion genes suggests a role in the oncogenic process associated with this type of tumor.
nan
Predictive, Oncogenic evidence:
Predictive: The variant FGFR1 p.V561M is described as imparting resistance to FGFR inhibitors, indicating its role in predicting treatment response and resistance to therapy in the context of pilomyxoid astrocytomas.
Oncogenic: The study identifies the FGFR1 p.V561M variant as a gatekeeper mutation that contributes to tumor development by imparting resistance to inhibitors, suggesting its role in the oncogenic process of pilomyxoid astrocytomas.
nan
Predictive, Oncogenic evidence:
Predictive: The variant FGFR1 p.V561M is described as imparting resistance to FGFR inhibitors, indicating its role in predicting treatment response and resistance in the context of therapy for pilomyxoid astrocytomas.
Oncogenic: The study identifies the FGFR1 p.V561M variant as a gatekeeper mutation that contributes to the tumor's characteristics, suggesting its involvement in tumor development or progression.
nan
nan evidence:
Missing abstract
nan
Predictive, Diagnostic evidence:
Diagnostic: The study discusses the use of FISH analysis for screening ABL1 fusions in pediatric acute lymphoblastic leukemia (ALL), indicating that the presence of the NUP214-ABL1 fusion can be used to classify or confirm the disease. This suggests that the variant is associated with a specific subtype of leukemia, fulfilling the criteria for diagnostic evidence.
Predictive: The abstract mentions that ABL1 fusions are potentially targetable by kinase inhibitors, indicating a correlation between the presence of this variant and the response to specific therapies. This aligns with predictive evidence as it suggests that the variant may influence treatment options.
nan
Functional evidence:
Functional: The variant p.Ser695Leu in EZH2 is mentioned in the context of sequencing results, indicating that it is a mutation found in the patient. This suggests that the variant may alter the molecular function of the EZH2 protein, which is relevant to its role in cancer biology.
nan
nan evidence:
Missing abstract
nan
Oncogenic evidence:
Oncogenic: The study discusses the mechanism by which SRA737 and PARPi synergistically inhibit tumor cell growth, indicating that the variant S3C is involved in tumor development or progression, particularly in the context of PARPi-resistant cell lines. This suggests that the variant contributes to the oncogenic processes in these cancer cells.
nan
Predictive, Diagnostic evidence:
Predictive: The study discusses the addition of pembrolizumab to chemotherapy and its impact on disease-free survival (DFS) in patients with dMMR endometrial cancer, indicating a correlation between the dMMR phenotype and treatment response. The results show a significant hazard ratio for DFS in the dMMR population, suggesting that the variant's presence may predict a better response to the therapy.
Diagnostic: The abstract mentions the classification of patients based on their dMMR status, which is used to define a specific subtype of endometrial cancer. This indicates that the dMMR variant is associated with a particular disease phenotype, supporting its role as a diagnostic marker.
nan
Predictive, Prognostic evidence:
Predictive: The study reports that patients with dMMR/MSI-H endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel had a statistically significant reduction in the risk of death, indicating that the variant correlates with response to this specific therapy. The mention of hazard ratios and the context of treatment response supports this classification.
Prognostic: The results indicate a statistically significant overall survival benefit in patients treated with dostarlimab, with a specific hazard ratio reported for the dMMR/MSI-H population, suggesting that the variant correlates with disease outcome independent of therapy. This aligns with the definition of prognostic evidence.
nan
Predictive, Prognostic evidence:
Predictive: The study discusses the significant increase in progression-free survival among patients with dMMR-MSI-H tumors treated with dostarlimab, indicating that the variant correlates with response to this specific therapy. The results show a marked difference in progression-free survival rates between the dostarlimab and placebo groups, highlighting the predictive nature of the variant in relation to treatment efficacy.
Prognostic: The results also provide data on overall survival rates at 24 months, suggesting that the presence of the dMMR-MSI-H variant correlates with better survival outcomes independent of therapy. The hazard ratios reported for both progression-free survival and overall survival indicate that this variant has prognostic implications for patients with endometrial cancer.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses how alterations in specific tumor suppressor genes, including the Kras G12D variant, can identify patients likely to benefit from immune checkpoint inhibitors combined with chemotherapy, indicating a correlation with treatment response.
Oncogenic: The variant Kras G12D is part of a genetically engineered model used to assess its role in promoting tumor growth, demonstrating its contribution to tumor development in the context of lung cancer.
nan
Predictive, Diagnostic evidence:
Predictive: The study investigates the efficacy of Debio 1347, a selective inhibitor targeting FGFR1-3 fusions, in patients with solid tumors harboring these fusions, indicating a focus on treatment response. The mention of "objective response rate (ORR)" and the evaluation of efficacy directly relates to the predictive nature of the variant's impact on therapy response.
Diagnostic: The abstract states that the trial involved patients with tumors "harboring a functional FGFR1-3 fusion," which implies that the presence of these fusions is used to classify or define the patient population for the study, thus supporting a diagnostic classification.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study discusses the t(4;14) translocation as a characteristic found in approximately 15% of patients with multiple myeloma, indicating its role in classifying patients based on their genetic status. This classification is essential for understanding the disease and tailoring treatment approaches.
Predictive: The study evaluates the efficacy of dovitinib, an RTK inhibitor, in patients with relapsed or refractory multiple myeloma, specifically assessing the treatment response based on the presence of the t(4;14) translocation. The mention of treatment response rates in relation to the t(4;14) status suggests a predictive relationship between the variant and therapy outcomes.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the efficacy of fexagratinib, an FGFR inhibitor, in patients with recurrent FGFR-TACC + high-grade gliomas, indicating a correlation between the FGFR-TACC fusion and response to this specific therapy. The mention of a 32-gene signature associated with the benefit of FGFR inhibition further supports the predictive nature of the variant in relation to treatment response.
Oncogenic: The abstract states that FGFR-TACC fusions are oncogenic and present in high-grade gliomas, indicating that these somatic variants contribute to tumor development or progression. This classification is supported by the context of the study focusing on the safety and efficacy of a treatment targeting these specific fusions.
nan
Oncogenic evidence:
Oncogenic: The variant K27M is associated with the histone H3 K27M mutant protein, which is known to contribute to tumor development or progression in certain cancers, particularly gliomas. The mention of this specific mutant protein in the results section indicates its role in oncogenesis.
nan
Diagnostic evidence:
Diagnostic: The abstract discusses HGAP as an important consideration in the differential diagnosis of isocitrate dehydrogenase-wild-type gliomas, indicating that the variant is used to classify or define a disease subtype. Additionally, it mentions the association with neurofibromatosis 1 syndrome, further supporting its role in diagnosis.
nan
Diagnostic, Predisposing evidence:
Diagnostic: The study discusses the identification of germline mutations in patients with pheochromocytomas and paragangliomas (PPGLs), indicating that these variants can lead to an early diagnosis of multiple or more aggressive tumors, which aligns with the use of variants to define or confirm a disease.
Predisposing: The mention of germline mutations in patients with PPGLs suggests an inherited risk for developing these tumors, particularly in younger patients, which supports the classification of these variants as predisposing.
nan
Predictive, Prognostic, Oncogenic evidence:
Predictive: The study discusses the variant G2032R in the context of acquired resistance mutations, indicating that taletrectinib shows robust activity against this variant, which correlates with treatment response. This suggests that the presence of G2032R may influence the effectiveness of taletrectinib therapy in patients with NSCLC.
Prognostic: The results mention prolonged progression-free survival associated with taletrectinib treatment, which implies that the presence of the G2032R variant may correlate with disease outcome independent of therapy. This indicates that the variant could have implications for patient prognosis in the context of treatment with taletrectinib.
Oncogenic: The mention of G2032R as an acquired resistance mutation suggests that it contributes to tumor progression or development, particularly in the context of resistance to therapy. This aligns with the definition of an oncogenic variant, as it is involved in the cancer's response to treatment.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the drug sensitivity and resistance of the exon 20 insertion variants, specifically mentioning that they have lower sensitivity to 1st-3rd generation EGFR TKIs and that newer inhibitors like BAY-568, TAS6417, and TAK-788 show selective inhibition, indicating a correlation with treatment response.
Oncogenic: The abstract highlights that somatic mutations in EGFR, including the exon 20 insertions, are frequent drivers of non-small cell lung cancer (NSCLC), which supports the notion that these variants contribute to tumor development and progression.
nan
Predictive evidence:
Predictive: The study demonstrates that treatment with osimertinib significantly improves progression-free survival in patients with unresectable EGFR-mutated NSCLC, indicating a correlation between the EGFR mutation and response to this specific therapy. The results show a median progression-free survival of 39.1 months with osimertinib compared to 5.6 months with placebo, highlighting the predictive nature of the EGFR variant in treatment outcomes.
nan
Predictive, Diagnostic evidence:
Diagnostic: The variant M34 is associated with the pathology diagnosis of LUSC (lung squamous cell carcinoma) in the context of the study, indicating its relevance in defining or classifying this disease subtype.
Predictive: The results indicate that patients with the M34 variant received first-line treatment with chemo+pembrolizumab, and the best response was complete response (CR), suggesting a correlation between this variant and treatment response.
nan
Prognostic, Functional evidence:
Prognostic: The abstract mentions that "Osteosarcoma (OS) patients with metastasis or recurrent tumors still suffer from poor prognosis," indicating a correlation between the variant and disease outcome independent of therapy.
Functional: The study discusses how treatment with the DNA demethylating agent 5-aza-2'-deoxycytidine (5-aza-dC) "markedly suppressed their growth" and "multiple tumor-suppressor and osteo/chondrogenesis-related genes were re-activated," suggesting that the variant alters molecular function related to gene expression and cellular behavior.
nan
Predictive evidence:
Predictive: The abstract indicates that selective TRK inhibition by larotrectinib is a therapeutic option specifically for IFS carrying the ETV6-NTRK3 gene fusion, suggesting a correlation between this variant and response to therapy. This aligns with the definition of predictive evidence, as it discusses the effectiveness of a treatment based on the presence of a specific variant.
nan
Diagnostic, Prognostic evidence:
Diagnostic: The study discusses kataegis in the context of breast cancer subgroups defined by ER, PR, and HER2/ERBB2 status, indicating its role in classifying and associating with specific tumor characteristics and aggressive phenotypes.
Prognostic: The abstract mentions that kataegis status was associated with aggressive characteristics in certain breast cancer subgroups, suggesting a correlation with disease outcome, particularly in ERpHER2n tumors.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with specific genomic alterations in childhood B-lineage ALL, indicating that these genetic lesions can be used to classify and define this high-risk subtype of leukemia.
Predictive: The findings suggest that the identified targetable genetic lesions, such as CRLF2 rearrangements and ABL-class fusions, may correlate with treatment approaches in precision medicine for Ph-like ALL, indicating their potential role in predicting response to targeted therapies.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with high-risk childhood B-lineage ALL, indicating that specific genetic alterations can be used to classify and define this subtype of leukemia.
Predictive: The findings suggest that the identified targetable genetic lesions, such as CRLF2 rearrangements and ABL-class fusions, may correlate with treatment approaches in precision medicine for Ph-like ALL, indicating potential sensitivity to specific therapies.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with specific genetic alterations in childhood B-lineage ALL, indicating its role in classifying this high-risk subtype of leukemia.
Predictive: The findings support a precision-medicine approach for Ph-like ALL, suggesting that the identified genetic lesions may correlate with response to targeted therapies, which is a key aspect of treatment for this subtype.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with specific genetic alterations in childhood B-lineage ALL, indicating its role in classifying this high-risk subtype of leukemia. The mention of the frequency of CRLF2 rearrangements and other genetic lesions further supports the use of these variants in defining the disease.
Predictive: The findings suggest that the identified genetic alterations, including CRLF2 rearrangements and other targetable lesions, may correlate with treatment approaches in precision medicine for Ph-like ALL, indicating their potential impact on therapy response. The emphasis on targetable genetic lesions implies a relationship with treatment strategies.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with high-risk childhood B-lineage ALL, indicating that specific genomic alterations can be used to classify and define this subtype of leukemia.
Predictive: The findings suggest that the identified targetable genetic lesions, such as CRLF2 rearrangements and ABL-class fusions, may correlate with treatment approaches in precision medicine for Ph-like ALL, indicating potential sensitivity to specific therapies.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with specific genetic alterations in childhood B-lineage ALL, indicating that these variants can be used to classify and define this high-risk subtype of leukemia.
Predictive: The findings suggest that the identified genetic lesions, including CRLF2 rearrangements and other targetable alterations, may correlate with treatment response in the context of precision medicine for Ph-like ALL, highlighting their potential role in guiding therapy.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the Ph-like gene expression profile and its association with specific genetic alterations in childhood B-lineage ALL, indicating its role in classifying this high-risk subtype of leukemia. The mention of the frequency of CRLF2 rearrangements and other genomic alterations further supports the use of these variants in defining the disease.
Predictive: The findings suggest that the identified genetic lesions, including CRLF2 rearrangements and other targetable alterations, may correlate with treatment approaches in precision medicine for Ph-like ALL, indicating their potential impact on therapy response. The emphasis on targetable genetic lesions implies a relationship with treatment strategies.
nan
Diagnostic, Prognostic evidence:
Prognostic: The study reports that higher numbers of somatic mutations and copy number alterations (CNAs) significantly correlated with worse survival, indicating that these genetic alterations are associated with disease outcomes independent of therapy. Additionally, it identifies specific mutations and amplifications, such as PD-L1, as independent poor prognostic factors in aggressive ATL, further supporting the prognostic nature of these findings.
Diagnostic: The abstract mentions that aggressive and indolent ATL subtypes are associated with different genetic alterations, which helps classify the disease into molecularly distinct subsets. This classification based on genetic profiles indicates the use of these variants in defining and understanding the disease subtypes.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the association of the L858R mutation with treatment outcomes, indicating that patients with this mutation have a similar overall survival (OS) compared to those with uncommon, actionable variants when treated with first-line EGFR inhibitors. This suggests that the presence of the L858R variant correlates with response to therapy, which is a key aspect of predictive evidence.
Oncogenic: The abstract mentions that activating mutations in EGFR, including L858R, are a common mechanism of malignant transformation in non-small cell lung cancer (NSCLC). This indicates that the L858R variant contributes to tumor development, supporting its classification as oncogenic.
nan
Predictive, Prognostic evidence:
Predictive: The abstract mentions that testing for driver mutations identifies patients who benefit from TKI-therapy, indicating that the presence of such mutations, including T790M, correlates with response to specific therapies. Additionally, the results highlight that the presence of a driver mutation predicts response to specific TKIs, further supporting the predictive nature of the T790M variant in the context of treatment.
Prognostic: The results section states that EGFR-positive NSCLC is associated with improved prognosis, suggesting that the presence of the T790M variant may correlate with disease outcomes independent of therapy. This indicates that T790M could have prognostic implications in the context of NSCLC.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The variant p.V617F is mentioned as a major diagnostic criterion for the diagnosis of Polycythemia Vera (PV), indicating its role in defining and confirming the disease. The presence of this mutation is used to classify the disease, which aligns with the definition of a diagnostic evidence type.
Oncogenic: The mention of the JAK2 p.V617F mutation in the context of diagnostic criteria for PV suggests that it contributes to tumor development or progression, as it is a well-known somatic mutation associated with myeloproliferative neoplasms. This aligns with the oncogenic evidence type, as it indicates the variant's role in the pathogenesis of the disease.
nan
nan evidence:
Parsing error: argument of type 'NoneType' is not iterable
nan
Predictive, Diagnostic evidence:
Diagnostic: The study evaluates the immunophenotypes and karyotypes of patients with childhood acute lymphoblastic leukemia (ALL) associated with the t(1;19) and der(19)t(1;19) translocations, suggesting that these variants can be used to classify distinct subtypes of ALL.
Predictive: The results indicate that patients with the t(1;19) and der(19)t(1;19) translocations did not respond to therapy as well as those with early pre-B ALL, highlighting the predictive nature of these variants in terms of treatment response.
nan
Predictive, Diagnostic evidence:
Predictive: The identification of the COL1A1-PDGFB gene fusion allows greater choice of targeted therapy in these patients, indicating that the variant correlates with response to specific therapies.
Diagnostic: The COL1A1-PDGFB gene fusion is associated with a specific subtype of uterine sarcoma, which supports its use in defining and classifying this disease entity.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study identifies the SH3PXD2A::HTRA1 fusion in schwannomas and discusses its prevalence and association with specific clinicopathologic characteristics, indicating its role in defining and classifying these tumors. The mention of "fusion-positive schwannomas" and their distinct features supports the classification of this variant as a diagnostic marker.
Predictive: The study establishes a correlation between the presence of the SH3PXD2A::HTRA1 fusion and specific histological features, such as the 'serpentine' palisading pattern, which can predict fusion status with high sensitivity and specificity. This suggests that the variant may be used to predict certain characteristics of the tumors, aligning with predictive evidence.
nan
nan evidence:
Based on the provided information, there are no mentions of the variant in either the abstract or the results section. Therefore, I cannot classify any evidence type as there is no supporting text to justify a classification.
nan
nan evidence:
Parsing error: argument of type 'NoneType' is not iterable
nan
Diagnostic, Oncogenic evidence:
Oncogenic: The abstract discusses the identification of EGFR internal tandem duplications (ITD) in tumors, specifically noting their presence in congenital mesoblastic nephromas and other pediatric sarcomas. This suggests that the EGFR ITD contributes to tumor development or progression in these specific cancer types.
Diagnostic: The study highlights the association of EGFR ITD with specific tumor types, particularly in pediatric sarcomas, indicating its role in defining or classifying these tumors. The identification of this variant in a subset of tumors supports its use as a biomarker for diagnosis.
nan
Prognostic evidence:
Prognostic: The study indicates that adult patients with t(1;19)(q23;p13) positive ALL had a favorable prognosis, as evidenced by the reported 5-year cumulative incidence of relapse and overall survival rates. This suggests that the variant correlates with disease outcome independent of therapy.
nan
Diagnostic, Prognostic evidence:
Prognostic: The study indicates that the t(1;19) variant is an independent risk factor for isolated CNS relapse, suggesting that it correlates with disease outcome independent of therapy. This is supported by the mention of event-free survival and the cumulative incidence of relapse in patients with this variant.
Diagnostic: The t(1;19) is used to classify and define a specific subtype of B-cell precursor acute lymphoblastic leukemia (ALL), as indicated by its association with the TCF3/PBX1 fusion. This classification is crucial for understanding the disease and its treatment implications.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study discusses the t(1;19) chromosomal translocation as being observed in 25% of children with pre-B-cell acute lymphoblastic leukemia (ALL) and highlights its association with an adverse treatment outcome, indicating its role in defining and classifying the disease. The detection of E2A/PBX1 fusion transcripts in a majority of cases further supports its use as a biomarker for this subtype of leukemia.
Oncogenic: The findings suggest that the E2A/PBX1 fusion resulting from the t(1;19) translocation is an important pathogenic event in t(1;19) ALL, indicating that this somatic variant contributes to tumor development or progression in this specific leukemia type.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study discusses the t(1;19) translocation and its association with acute lymphoblastic leukemia (ALL), indicating that it is a common genetic alteration used to classify the disease. The mention of different mechanisms leading to the formation of the der(19) and the investigation of markers proximal to the breakpoint further supports its role in defining the disease subtype.
Oncogenic: The t(1;19) translocation is described as one of the most common translocations in ALL, suggesting that it contributes to tumor development or progression. The study's focus on the mechanisms of how the der(19) arises indicates its potential role in oncogenesis within the context of leukemia.
nan
nan evidence:
Missing abstract
nan
Predictive, Diagnostic evidence:
Diagnostic: The study discusses the identification of patients with E2A-PBX1 positive translocations, indicating that the presence of this specific variant is used to classify and confirm a subtype of acute lymphoblastic leukemia (ALL). The development of a fluorescence in situ hybridization assay to detect E2A translocations further supports its role as a diagnostic tool in identifying patients who require specific therapeutic interventions.
Predictive: The abstract mentions that more intensive therapy improves the outcome of patients with E2A-PBX1 positive translocations, suggesting that the presence of this variant correlates with response to therapy. This highlights the importance of identifying this subset of patients to administer appropriate treatment, which aligns with predictive evidence.
nan
Oncogenic evidence:
Oncogenic: The study discusses the translocation t(12;16)(q13:p11) in malignant myxoid liposarcoma, indicating that it results in a fusion of the CHOP gene with the FUS gene, which contributes to tumor development. This suggests that the variant plays a role in the oncogenic process by creating a fusion protein that may drive tumorigenesis.
nan
Prognostic evidence:
Prognostic: The study demonstrates the prognostic significance of genetic alterations within subtypes of acute lymphoblastic leukemia (ALL), indicating that these alterations correlate with disease outcomes. This suggests that the presence of specific genetic changes can provide insights into the prognosis of patients with different ALL subtypes.
nan
Prognostic evidence:
Prognostic: The study demonstrates the prognostic significance of genetic alterations within subtypes of acute lymphoblastic leukemia (ALL), indicating that these alterations correlate with disease outcomes. This suggests that the presence of specific genetic changes can provide insights into the prognosis of patients with ALL.
nan
Prognostic evidence:
Prognostic: The study demonstrates the prognostic significance of genetic alterations within subtypes of acute lymphoblastic leukemia (ALL), indicating that these alterations correlate with disease outcomes. This suggests that the presence of specific genetic changes can provide insights into the prognosis of patients with ALL.
nan
nan evidence:
Parsing error: argument of type 'NoneType' is not iterable
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the efficacy of BI-4732 in overcoming osimertinib resistance mediated by the C797S variant, indicating that this variant correlates with resistance to therapy and highlights the potential for BI-4732 as a treatment option.
Oncogenic: The C797S variant is implicated in osimertinib resistance, suggesting that it contributes to tumor progression and development, as evidenced by the preclinical models used in the study.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the resistance to CDK4/6 inhibitors in KRAS-mutant non-small cell lung cancer (NSCLC) and how the inhibition of BRD4 can enhance the efficacy of these inhibitors, indicating a correlation with treatment response. The mention of "synergized with palbociclib to induce senescence" suggests that the variant's presence affects the sensitivity to therapy.
Oncogenic: The abstract indicates that BRD4 overexpression contributes to resistance against CDK4/6 inhibitors in KRAS-mutant NSCLC cells, suggesting that this variant plays a role in tumor progression and development. The context of BRD4's involvement in enhancing cell cycle arrest and promoting senescence further supports its oncogenic role.
nan
Predictive evidence:
Predictive: The abstract mentions that PLX8725 demonstrates promising in vivo activity against PDX models of uLMS harboring GOF alterations in the MAP2K4 gene, indicating a correlation between the variant and response to the therapy. This suggests that the variant may influence treatment sensitivity, warranting further clinical trials.
nan
Predictive, Oncogenic evidence:
Predictive: The study evaluates the response to divarasib, a KRAS G12C inhibitor, in patients with tumors harboring the KRAS G12C mutation, indicating that the variant correlates with treatment response. The mention of "biomarkers of response and resistance" further supports the predictive nature of the evidence regarding therapy outcomes.
Oncogenic: The KRAS G12C mutation is described as a target for the covalent inhibitor divarasib, suggesting that this somatic variant contributes to tumor development or progression. The context of the study focuses on advanced or metastatic solid tumors that harbor this mutation, reinforcing its role in oncogenesis.
nan
Predictive evidence:
Predictive: The study indicates that SRSF2- and U2AF1-mutant leukemias are preferentially sensitive to PARP inhibitors, suggesting a correlation between these mutations and response to therapy. The mention of "PARPi sensitivity" and "PARP1 activity could be predictive of PARPi sensitivity" directly supports the predictive nature of the variant's role in treatment response.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the efficacy of the PRMT5 methyltransferase inhibitor MRTX1719 in selectively killing cancers that are codeleted for CDKN2A and MTAP, indicating a correlation between the CDKN2A/MTAP codeletion and response to this specific therapy. This suggests that the presence of the variant is predictive of treatment response in clinical trials for solid tumors.
Oncogenic: The abstract mentions that CDKN2A is the most common homozygously deleted gene in all human cancers, indicating that its deletion contributes to tumor development or progression. This supports the classification of CDKN2A as an oncogenic variant due to its role in cancer biology.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study identifies NRG1 fusions as occurring in 0.36% of lung adenocarcinoma cases and discusses their prevalence among specific pathologic subtypes, indicating that these fusions can be used to classify or define a subset of lung cancer.
Oncogenic: The presence of NRG1 fusions, along with other fusions detected in the study, suggests that these alterations contribute to tumor development or progression in lung adenocarcinomas, as they are described in the context of profiling oncogenic drivers.
nan
Predictive evidence:
Predictive: The results indicate that the RET gatekeeper mutations V804L/M/E are specifically mentioned in the context of treatment with RET-specific TKIs, selpercatinib and pralsetinib, which are approved for RET-altered cancers. This suggests that these variants correlate with response to these therapies, highlighting their predictive nature regarding treatment efficacy.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study identifies the prevalence of the ERBB2DeltaEx16 variant, including c.1899-880_1946+761del, in Chinese pan-cancer patients, suggesting its role in defining or classifying a disease subtype within this population.
Oncogenic: The presence of the c.1899-880_1946+761del variant among the detected ERBB2DeltaEx16 variants indicates its potential contribution to tumor development or progression, as it is part of a broader category of variants associated with the ERBB2 gene in cancer.
nan
Predictive, Diagnostic evidence:
Predictive: The study reports that the patient carrying the HER2 G292R variant benefited from pyrotinib treatment after progression on prior therapies, indicating a correlation between this variant and a positive response to a specific therapy.
Diagnostic: The mention of the HER2 G292R variant in the context of a metastatic cervical adenocarcinoma patient suggests its role in defining or classifying the disease, particularly as it is associated with activating mutations in HER2 commonly found in this cancer type.
nan
Predictive, Diagnostic evidence:
Predictive: The study demonstrates that the p.L755P mutation correlates with a response to osimertinib treatment in a patient with NSCLC, indicating its potential as a predictive biomarker for therapy response.
Diagnostic: The mention of the p.L755P mutation in the context of defining the patient's cancer subtype (HER2 exon 19 mutation) suggests that this variant is used to classify or confirm the disease.
nan
Predictive, Prognostic evidence:
Predictive: The study assesses the efficacy of pyrotinib in patients with HER2-mutant advanced NSCLC, indicating that the presence of HER2 mutations correlates with response to this specific therapy, as evidenced by the reported objective response rate of 30.0%.
Prognostic: The median overall survival of 14.4 months for patients with HER2-mutant NSCLC suggests that this variant may correlate with disease outcome, independent of therapy, providing prognostic information about the survival of these patients.
nan
Predictive, Prognostic evidence:
Predictive: The study discusses the effectiveness of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer, indicating that the variant correlates with response to this specific therapy, as evidenced by the significant differences in progression-free survival and overall survival between treatment groups.
Prognostic: The results show that patients with HER2-low metastatic breast cancer had different overall survival rates based on the treatment received, suggesting that the HER2-low status is associated with disease outcomes independent of therapy.
nan
Predictive, Prognostic evidence:
Predictive: The study discusses the effectiveness of trastuzumab deruxtecan in patients with HER2-low metastatic breast cancer, indicating that the variant correlates with response to this specific therapy, as evidenced by the significant improvement in progression-free survival and overall survival compared to the physician's choice of chemotherapy.
Prognostic: The results show that patients with HER2-low metastatic breast cancer had different overall survival rates based on the treatment received, suggesting that the HER2-low status is associated with disease outcomes independent of therapy, as indicated by the reported hazard ratios for death.
nan
Functional evidence:
Functional: The study discusses PAK4, a serine/threonine kinase, and its role in altering molecular functions related to cancer progression, such as controlling cell proliferation and survival. This indicates that the variant affects biochemical pathways and cellular behaviors, which aligns with the functional evidence type.
nan
Predictive, Oncogenic evidence:
Oncogenic: The study discusses the common mutations in FGFR3, specifically mentioning the S249 mutation, and indicates that these mutations contribute to tumor development, as they are described as "somatic activating mutations" that are prevalent in human cancer.
Predictive: The abstract mentions that the study evaluated the sensitivity of various FGFR mutations, including S249, to FGFR tyrosine kinase inhibitors (TKIs), indicating a correlation between the variant and response to therapy.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the potential of a combination treatment using DNA hypomethylating agents and PARP inhibitors specifically targeting SETD2-deficient cancers, indicating a correlation with treatment response in these cases. The mention of "synergistically increased cytotoxicity" in SETD2-deficient cell lines supports the predictive nature of the variant's role in therapy response.
Oncogenic: The abstract highlights that SETD2 deficiency plays a significant role in aggressive forms of cancer, particularly in clear cell renal cell carcinomas, suggesting that this somatic variant contributes to tumor development and progression. The context of "SETD2 deficiency alters the epigenetic landscape" further supports its oncogenic classification.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the KRASG12D mutation in the context of therapy, specifically mentioning the response to the MRTX1133 inhibitor and its effects on pancreatic adenocarcinoma (PDAC). The results indicate that MRTX1133 leads to regression of advanced PDAC and highlights the importance of CD8+ T cells and immune checkpoint blockade in enhancing treatment efficacy, which aligns with predictive evidence regarding therapy response.
Oncogenic: The KRASG12D mutation is described as being present in nearly half of pancreatic adenocarcinomas and is implicated in tumor development and progression, as evidenced by the use of various models of KRASG12D-driven PDAC. The study demonstrates that inhibiting this mutation leads to significant changes in tumor growth and microenvironment, supporting its role as an oncogenic driver.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses how FGFR2 fusions are associated with moderate response rates to FGFR inhibitors and highlights the emergence of resistance due to secondary mutations, indicating a correlation between the FGFR2 variant and treatment response. The findings suggest that combining FGFR and EGFR inhibitors could enhance therapeutic efficacy, further supporting the predictive nature of the FGFR2 variant in treatment contexts.
Oncogenic: The abstract mentions that FGFR2 fusions are present in cholangiocarcinoma and that these fusions contribute to tumor development and progression, as evidenced by the therapeutic studies conducted on patient-derived models. This indicates that the FGFR2 variant plays a role in oncogenesis within this cancer type.
nan
Predictive, Diagnostic evidence:
Predictive: The study discusses the clinical activity of pralsetinib, a selective RET inhibitor, in patients with RET fusion-positive NSCLC, indicating a correlation between the presence of the RET fusion and the response to this specific therapy. The overall response rates reported for treatment-naive patients and those with prior chemotherapy further support this predictive evidence.
Diagnostic: The presence of RET fusions is highlighted as a defining characteristic in the context of non-small-cell lung cancer (NSCLC), suggesting that these variants are used to classify patients with this disease subtype. The mention of RET fusion-positive NSCLC indicates its role as a biomarker for diagnosis.
nan
Functional evidence:
Functional: The variant D9E is mentioned in the context of pAKT-S473, indicating that it is associated with the phosphorylation state of AKT, which suggests that it alters molecular function related to signaling pathways in breast cancer cells. This aligns with the definition of functional evidence as it focuses on the biochemical activity of the protein.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses how specific FGFR3 mutations, including N540K, result in distinct changes in drug efficacy when treated with various inhibitors, indicating a correlation between the variant and response to therapy.
Oncogenic: The abstract mentions that certain mutations in FGFRs, including N540K, are implicated as drivers in diverse tumors, suggesting their role in tumor development or progression.
nan
Predictive, Diagnostic evidence:
Diagnostic: The study discusses the presence of the R678Q mutation in various breast cancer subtypes, indicating its association with specific histological types such as invasive lobular carcinoma (ILC) and invasive ductal carcinoma (IDC). This suggests that the variant can be used to classify or define the disease based on tumor type.
Predictive: The abstract mentions that patients carrying the R678Q mutation seem to be good candidates for anti-HER2 therapy, as they show favorable outcomes and a good response to current pharmacological treatments. This indicates a correlation between the variant and the response to therapy, classifying it as predictive evidence.
nan
Oncogenic evidence:
Oncogenic: The introduction of the ERBB2 mutation S310F into human pancreatic epithelial cells causes oncogenic transformation, increasing ERBB2 signaling and promoting tumor growth, indicating that it contributes to tumor development.
nan
Oncogenic evidence:
Oncogenic: The abstract discusses the KRAS protein as a common driver in human cancer, indicating that mutations in KRAS, including those at the Q61 position, contribute to tumor development and progression. The results section further emphasizes the oncogenic nature of KRAS mutations, particularly highlighting their prevalence in various cancers.
nan
nan evidence:
There are no mentions of the variant in the abstract or results section provided. Therefore, no CIViC evidence types can be classified based on the information given.
nan
Predictive, Oncogenic evidence:
Predictive: The study indicates that the ALK Arg1275Gln mutation is the only mutation predicted to be sensitive to ALK inhibition with crizotinib, suggesting a correlation between this variant and response to therapy.
Oncogenic: The presence of the somatic ALK Arg1275Gln mutation is described as the most common ALK hotspot mutation observed in neuroblastoma, indicating its role in tumor development or progression.
nan
Predictive, Diagnostic evidence:
Predictive: The study discusses the response of patients with KRAS G12D-mutant NSCLC to bortezomib, indicating that exceptional responses can be achieved, which correlates with treatment sensitivity. The mention of "KRAS G12D mutation alone, however, is not a robust predictor of response" suggests a nuanced relationship between the variant and therapy response.
Diagnostic: The abstract states that patients with advanced KRAS G12D-mutant NSCLC were eligible for the trial, indicating that the presence of this variant is used to classify and define a specific subtype of lung cancer. This aligns with the use of the variant as a biomarker for patient selection in clinical trials.
nan
Oncogenic, Functional evidence:
Functional: The study discusses the variant E401G in the context of its location in the extracellular domain of the ERBB2 gene, indicating that functional analyses of such variants have been limited, which suggests an exploration of how this variant may alter molecular function.
Oncogenic: The mention of ERBB2 gene alterations, including the E401G variant, as promising target alterations in cancer treatment implies that this variant may contribute to tumor development or progression, aligning with oncogenic behavior.
nan
Predictive, Functional evidence:
Predictive: The study indicates that patients with the S310F mutation responded to trastuzumab with or without the pertuzumab combination, suggesting a correlation between the variant and treatment response. This aligns with the predictive evidence type as it discusses the variant's impact on therapy effectiveness.
Functional: The research demonstrates that the S310F mutant HER2 can form an active heterodimer with EGFR, which is a functional alteration in molecular interactions. This evidence supports the functional type as it focuses on the biochemical behavior of the variant in relation to receptor activation and dimerization.
nan
Predictive, Oncogenic evidence:
Predictive: The study discusses the emergence of the ESR1 Y537S mutation in the context of resistance to CDK4/6 inhibitors, indicating that this variant may correlate with treatment resistance, which is a key aspect of predictive evidence.
Oncogenic: The emergence of the ESR1 Y537S mutation is implicated in the development of resistance mechanisms during treatment, suggesting that this somatic variant contributes to tumor progression in the context of advanced breast cancer.
nan
Functional evidence:
Functional: The study discusses the effects of various treatments on the expression of cyclin E and the levels of phosphorylated histone variant H2AX (gammaH2AX), indicating that the variant E in 72 alters molecular function related to DNA damage response and cell cycle regulation. This is supported by the immunoblotting results showing changes in protein expression levels in response to treatment.
nan
Predictive, Oncogenic evidence:
Predictive: The study indicates that HP breast cancers with the HER2V777L mutation show resistance to the pan-HER tyrosine kinase inhibitor, neratinib, but respond effectively to the combination of neratinib and trastuzumab deruxtecan, demonstrating a correlation between the variant and treatment response.
Oncogenic: The presence of the HER2V777L mutation is associated with accelerated tumor formation and increased invasion and migration in breast cancer models, indicating that this somatic variant contributes to tumor development and progression.
nan
Diagnostic, Functional evidence:
Functional: The study discusses the functional analysis of RAD51C variants, including p.Leu262Val (L262V), indicating that this variant was predicted to cause aberrant splicing based on the Splice AI algorithm. This suggests that the variant alters molecular function, specifically splicing activity.
Diagnostic: The abstract mentions that the analysis provides information for the classification of the cancer relevance of RAD51C variants, implying that variants like p.Leu262Val (L262V) are used to define or classify disease relevance, which aligns with diagnostic evidence.
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study describes the GAB1::ABL1 fusion as a distinct entity in soft tissue tumors, indicating its role in defining and classifying these tumors. The mention of various tumor types harboring this fusion supports its use as a biomarker for diagnosis.
Oncogenic: The presence of the GAB1::ABL1 fusion in the tumors suggests that it contributes to tumor development or progression, as the study focuses on tumors characterized by this specific genetic alteration. The characterization of these tumors as a distinct entity further implies a role in oncogenesis.
nan
Predictive, Oncogenic evidence:
Oncogenic: The abstract states that canonical mutations in the PIK3CA gene promote oncogenesis via specific signaling pathways, indicating that these somatic variants contribute to tumor development.
Predictive: The abstract mentions that these mutations may serve as predictive biomarkers of response to PI3K inhibitors and NSAID therapy, suggesting a correlation with treatment response.
nan
Oncogenic, Functional evidence:
Oncogenic: The study describes how PIK3CA mutations were assessed for their activity in promoting tumor growth and transformation, indicating that these somatic variants contribute to tumor development or progression.
Functional: The research highlights that specific PIK3CA variants exhibit variant-specific activation of PI3K signaling and other pathways, demonstrating that these mutations alter molecular function, which was assessed through in vitro and in vivo assays.
nan
Predictive, Functional evidence:
Functional: The study evaluated the transforming activities of the G776V mutation, indicating that it is an activating mutation. This suggests that the variant alters molecular function, which is a key aspect of the functional evidence type.
Predictive: The abstract discusses the varying sensitivities of ERBB2 mutations, including G776V, to ERBB2-targeted inhibitors like afatinib and neratinib. This indicates a correlation between the variant and response to specific therapies, which aligns with the predictive evidence type.
nan
nan evidence:
Missing abstract
nan
Diagnostic, Oncogenic evidence:
Diagnostic: The study discusses the diagnostic yield of PIK3CA sequencing in patients with PIK3CA-related overgrowth spectrum (PROS), indicating that the variant is used to define and confirm the disease, as evidenced by the identification of disease-causing mutations in 66.7% of patients. The results also highlight the importance of specific tissue samples for optimal diagnosis, further supporting its role as a diagnostic marker.
Oncogenic: The abstract mentions the identification of strong oncogenic mutations in patients with PIK3CA-related overgrowth spectrum, suggesting that these somatic variants contribute to tumor development or progression. The differential frequency of these mutations in patients with and without brain overgrowth further supports their oncogenic potential.